[go: up one dir, main page]

BR112021017661A2 - Uso de compostos 8,9-di-hidrocanabidiol - Google Patents

Uso de compostos 8,9-di-hidrocanabidiol

Info

Publication number
BR112021017661A2
BR112021017661A2 BR112021017661A BR112021017661A BR112021017661A2 BR 112021017661 A2 BR112021017661 A2 BR 112021017661A2 BR 112021017661 A BR112021017661 A BR 112021017661A BR 112021017661 A BR112021017661 A BR 112021017661A BR 112021017661 A2 BR112021017661 A2 BR 112021017661A2
Authority
BR
Brazil
Prior art keywords
compounds
dihydrocannabidiol
seizures
mitigating
treating
Prior art date
Application number
BR112021017661A
Other languages
English (en)
Inventor
Mark Mascal
Nikolay Shevchenko
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112021017661A2 publication Critical patent/BR112021017661A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/26—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

uso de compostos 8,9-dihidrocanabidiol. a presente invenção refere-se a um método de tratamento ou mitigação de convulsões compreendendo compostos como descrito neste documento.
BR112021017661A 2019-03-08 2020-03-09 Uso de compostos 8,9-di-hidrocanabidiol BR112021017661A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815735P 2019-03-08 2019-03-08
PCT/US2020/021670 WO2020185661A1 (en) 2019-03-08 2020-03-09 Use of 8,9-dihydrocannabidiol compounds

Publications (1)

Publication Number Publication Date
BR112021017661A2 true BR112021017661A2 (pt) 2021-11-16

Family

ID=72426794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017661A BR112021017661A2 (pt) 2019-03-08 2020-03-09 Uso de compostos 8,9-di-hidrocanabidiol

Country Status (8)

Country Link
US (1) US20250152520A2 (pt)
EP (1) EP3935037A4 (pt)
JP (1) JP7620984B2 (pt)
CN (1) CN113874344B (pt)
AU (1) AU2020236953A1 (pt)
BR (1) BR112021017661A2 (pt)
CA (1) CA3132841A1 (pt)
WO (1) WO2020185661A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168491A1 (en) * 2020-01-24 2021-07-29 Perkinelmer Health Sciences, Inc. Cannabinoid derivatives
WO2022105810A1 (zh) * 2020-11-17 2022-05-27 中国科学院上海药物研究所 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用
WO2024006896A1 (en) * 2022-06-29 2024-01-04 The Regents Of The University Of California Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome
WO2025078811A1 (en) * 2023-10-10 2025-04-17 Jazz Pharmaceuticals Research Uk Limited Cannabinoid compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018777A (en) * 1975-11-14 1977-04-19 Abbott Laboratories 2-Substituted-5-alkyl resorcinols
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
WO2017008136A2 (en) * 2015-07-16 2017-01-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Flourinated cbd compounds, compositions and uses thereof
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
CN109106699A (zh) * 2017-06-23 2019-01-01 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途

Also Published As

Publication number Publication date
AU2020236953A1 (en) 2021-09-30
CN113874344B (zh) 2025-05-27
US20220183998A1 (en) 2022-06-16
EP3935037A1 (en) 2022-01-12
CA3132841A1 (en) 2020-09-17
EP3935037A4 (en) 2023-03-22
US20250152520A2 (en) 2025-05-15
JP7620984B2 (ja) 2025-01-24
CN113874344A (zh) 2021-12-31
WO2020185661A1 (en) 2020-09-17
JP2022525038A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
BR112021017661A2 (pt) Uso de compostos 8,9-di-hidrocanabidiol
JOP20210105A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
SA520411125B1 (ar) Nlrp مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط
MX2023011282A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
MX2020011564A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA201892147A1 (ru) Бициклические соединения
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
CL2021003513A1 (es) Compuestos heterocíclicos, como inhibidores de bet; composición, útil para tratar cáncer.
EA202091906A1 (ru) Предотвращение или уменьшение роста растений путем биоцементации
MX2021003170A (es) Moduladores de la expresion de pnpla3.
ZA202309446B (en) Rapamycin analogs and uses thereof
CO2022000481A2 (es) Inhibidores de enzimas
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
CL2021003373A1 (es) Nuevos inhibidores de egfr
MA50398A (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
MX2021004710A (es) Compuestos polimorficos y usos de los mismos.
MX2021010152A (es) Moduladores de la expresion de malat1.
PE20210109A1 (es) Moduladores de la expresion de irf4
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]